Pancreatic Cancer Research

ResearcherUniversité de BordeauxActive in the last 2 years

V. Vendrely

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8627-4616; OpenAlex author ID A5038199519. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 4 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 14

  1. Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study. Co-author DOI 10.1016/j.esmogo.2025.100144↗
  2. Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: "Pancreat… Last author DOI 10.1016/j.annonc.2024.05.003↗
  3. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  4. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery. Last author DOI 10.1080/0284186x.2021.1944662↗
  5. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Co-author DOI 10.1053/j.gastro.2019.12.009↗
  6. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. Last author DOI 10.1016/j.dld.2019.03.004↗
  7. CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.tranon.2019.07.009↗
  8. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRE… Co-author DOI 10.1245/s10434-018-6931-6↗
  9. High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Su… Co-author DOI 10.3390/cancers11111656↗
  10. [Role of radiation therapy in the management of pancreatic cancer]. Co-author DOI 10.1016/j.canrad.2018.06.005↗
  11. A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. Co-author DOI 10.1186/s12885-018-4906-4↗
  12. Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model. Co-author DOI 10.1016/j.canlet.2017.01.002↗
  13. Chemoradiation for Unresectable Pancreatic Cancer Can Improve Quality of Life and Does Not Exclude Potential Resection. First author DOI 10.1016/j.ijrobp.2017.05.032↗
  14. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Co-author DOI 10.1148/radiol.14132914↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. F. Huguet · 4 shared papers, 2017–2024 · strength 0.53
  2. Christophe Laurent · 6 shared papers, 2014–2021 · strength 0.45
  3. Étienne Buscail · 5 shared papers, 2017–2021 · strength 0.41
  4. L. Chiche · 5 shared papers, 2014–2021 · strength 0.38
  5. Sandrine Dabernat · 4 shared papers, 2017–2019 · strength 0.30
  6. Jean‐Frédéric Blanc · 3 shared papers, 2014–2021 · strength 0.23
  7. Mauro Loi · 1 shared paper, 2024 · strength 0.20
  8. M. Hawkins · 1 shared paper, 2024 · strength 0.20
  9. Anna M E Bruynzeel · 1 shared paper, 2024 · strength 0.20
  10. Marta Scorsetti · 1 shared paper, 2024 · strength 0.20
  11. Christelle Bouchart · 1 shared paper, 2024 · strength 0.20
  12. Eva Versteijne · 1 shared paper, 2024 · strength 0.20
  13. Joost J.M.E. Nuyttens · 1 shared paper, 2024 · strength 0.20
  14. Claudia Pouypoudat · 2 shared papers, 2019–2021 · strength 0.19
  15. Christophe Cassinotto · 2 shared papers, 2014–2019 · strength 0.12
  16. António Sá Cunha · 2 shared papers, 2014–2019 · strength 0.11
  17. Mario Terlizzi · 1 shared paper, 2021 · strength 0.11
  18. Pascal R. Hammel · 1 shared paper, 2018 · strength 0.11
  19. Catherine Alix‐Panabières · 1 shared paper, 2019 · strength 0.08
  20. Jean‐Robert Delpéro · 1 shared paper, 2019 · strength 0.07
  21. Daniel Pietrasz · 1 shared paper, 2019 · strength 0.07
  22. Olivıer Turrini · 1 shared paper, 2019 · strength 0.07
  23. Alain Sauvanet Sauvanet · 1 shared paper, 2019 · strength 0.07
  24. Fabienne Portales · 1 shared paper, 2019 · strength 0.07
  25. Olivia Hentic Dhome · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.